CARE (Corona Accelerated R&D in Europe),
supported by Europe’s Innovative Medicines Initiative (IMI), is the largest
undertaking of its kind dedicated to discovering and developing urgently needed
treatment options for COVID-19. The initiative is committed to a long-term
understanding of the disease and development of therapies for COVID-19 and
future coronavirus threats in addition to urgent efforts to repurpose existing
therapies as potential immediate response. The CARE consortium will accelerate
COVID-19 R&D by bringing together the leading expertise and projects of 37
teams from academic and non-profit research institutions and pharmaceutical
companies into a comprehensive drug discovery engine.
Complete news release here.
